drugset / Trial / NCT07246187

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

NCT07246187

Phase 3 Recruiting 114 enrolled Mercy Bon Secours Saint Vincent Medical Center
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.

Timeline

Start
2025-11-06
Primary completion
2026-10-31
Completion
2026-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 5 mg Intramuscular
Comparator Olanzapine Small molecule 10 mg Intramuscular